Sep 18, 2015 at 10:46 | Source: Reuters
Aso said low US rates and outflow of capital into emerging economies have supported their growth since the global financial crisis, and that some countries are concerned about a capital flight that would be caused by rapid US rate hikes.
Sep 16, 2015 at 09:49 | Source: Moneycontrol.com
InSite Vision focuses on developing new specialty ophthalmic products, including three late stage programs.
Sep 14, 2015 at 13:39 | Source: Moneycontrol.com
Credit Suisse has build in USD 100 million in sales for Keveyis in FY17. Taro launched Keveyis at a high price of USD 163.8 per tablet of 50mg. This implies annual cost of USD 120,000 per patient.
Sep 07, 2015 at 07:51 | Source: CNBC
Sharp drops in the country's equities after a debt-fuelled rise earlier in the year have spooked domestic and international investors and forced Beijing to launch a raft of policies aimed at stemming further losses. Chinese stock markets are down nearly 40 percent from their June peak.
Sep 06, 2015 at 12:42 | Source: CNBC
They also said they were confident growth would pick up and, as a result, interest rates in "some advanced economies" -- code for the United States -- would have to rise.
Sep 05, 2015 at 12:48 | Source: PTI
In a meeting with Chinese Finance Minister Lou Jiwei here at the G20, US Treasury Secretary Jacob Lew said he was closely monitoring China's recent economic policy actions, including the shift in its exchange rate regime.
Aug 28, 2015 at 11:53 | Source: Reuters
While the Bank of Japan has said it will look through the effect of slumping oil costs on inflation, the weak figures will keep it under pressure to expand its massive stimulus programme.
Aug 25, 2015 at 16:36 | Source: CNBC
Earlier in the session, the Tokyo bourse had staged a comeback, alongside most of the other regional stock indices, on the back of bargain hunting in beaten-down stocks and as the Dow Jones Industrial Average futures opened up more than 100 points Monday evening in the US.
Aug 25, 2015 at 08:58 | Source: Reuters
Aso said that while there was no immediate plan for G20 and G7 nations to take coordinated action against the current markets turmoil, global financial authorities were in frequent contact with each other on market developments.
Aug 19, 2015 at 14:05 | Source: Moneycontrol.com
BoAML is betting big on Indian pharma companies as weak rupee is positive for the sector. It says Cadila, Aurobindo and Lupin are the biggest beneficiaries of a weak rupee while Sun Pharma would see a moderate impact as it has global operations.
Messages on Taro »


Platinum Member


Ranbaxy Labs  

One must understand that SUN cannot b redflagged bcs its main subsidiary is TARO is situated in Iserael which has more strintest practoces more than even USA.Also USA realised that by redflagging Indian cos like RBaxy it is USA public which is suffering bcs of nongen drugs produced by another

6.26 PM Jul 7th 2014


Platinum Member


Suven Life Scie  

That`s also a good strategy.Something I hear/read,even RJ follows.SLS management is conservative & Mr. Jasti has always been very candid about his company.Recently,they had achieved aprroval for Malathion,to be marketed by Taro.The bottomline will be 2MUSD every year from this product alone! See

9.23 PM Jul 3rd 2014


Silver Member


Sun Pharma  

Ultimately patience is paying rich dividends. Good to know Taro has shot up by more than 16%. Sun should open with a big gap monday morning. Cheers!

8.49 PM Jun 28th 2014


Gold Member


Sun Pharma  

Awsome Taro....16% up at 137 !! good news coming for sun pharma as well !!

6.53 PM Jun 28th 2014


Gold Member


Sun Pharma  

dear kurken...its other way buddy they will acquire mnc`s like taro,caraco,dusa etc...list not going to stop and its a professionally managed company...stay invested...

10.27 AM May 30th 2014


New Member



Guys: Hope you got benefitted by my buy call on Lupin today... all the pharma stocks buzzing Dr. Reddy, Lupin, Div lab... tomorrow sun pharma likely to post good results.. so continue buy Lupin as near term target is 960. Strong results of Taro is set to boost Sun Pharma`s Q4FY2014 results. Taro

4.06 PM May 28th 2014


New Member


Sun Pharmaceutical Industries  

Strong results of Taro is set to boost Sun Pharma`s Q4FY2014 results. Taro Pharma contributes near 48% of US revenue and 29% of total revenue. Sharekhan expect Sun Pharma to report a revenue of Rs4290 crore (39.7% YoY)and net profit of Rs1313 crore (29.8% YoY) in Q4FY2014. Sharekhan can expect

4.03 PM May 28th 2014

Sun Pharma  

Taro EPS up 44% for FY.

2.43 PM May 28th 2014

Sun Pharma  

Net income attributable to Taro was $360.4 million compared to $266.2 million, a $94.2 million increase, resulting in diluted earnings per share of $8.14 compared to $5.95 Net sales of $759.3 million, increased $88.3 million, or 13.2%, with a slight decrease in volumes Taro`s FY 14 results. EPS

2.42 PM May 28th 2014


New Member


Sun Pharma  

Taro posted spectacular results this time around. Sun Pharma will also post good results tomorrow. Exporters are doing good currently, so it is a good idea to buy sun pharma today, a combination of good results and short covering on expiry can easily take this stock to 600 levels. 580 can be used

1.54 PM May 28th 2014

News across the web »
Jul 22, 2015 at 14:59 | Source: FirstPost
Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.